Adaptimmune Therapeutics annual debt-to-assets ratio
2018
2019
2020
2021
2022
2023
2024
Adaptimmune Therapeutics Debt-to-Assets Ratio Growth & History (ADAPY)
Adaptimmune Therapeutics's debt-to-assets ratio was 0.30 for fiscal 2024.
View full Adaptimmune Therapeutics company overviewAdaptimmune Therapeutics annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 0.30 | 0.21 | +237.89% |
| 2023 | 2023-12-31 | 0.09 | 0.02 | +27.27% |
| 2022 | 2022-12-31 | 0.07 | 0.02 | +29.35% |
| 2021 | 2021-12-31 | 0.05 | 0.00 | +3.20% |
| 2020 | 2020-12-31 | 0.05 | −0.09 | −62.52% |
| 2019 | 2019-12-31 | 0.14 | 0.05 | +49.27% |
| 2018 | 2018-12-31 | 0.09 | — | — |
Adaptimmune Therapeutics quarterly debt-to-assets ratio
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | 0.37 | 0.23 | +153.19% |
| Q1 2025 | 2025-03-31 | 0.31 | 0.22 | +235.55% |
| Q4 2024 | 2024-12-31 | 0.30 | 0.21 | +237.89% |
| Q3 2024 | 2024-09-30 | 0.23 | 0.15 | +171.92% |
| Q2 2024 | 2024-06-30 | 0.15 | 0.07 | +91.63% |
| Q1 2024 | 2024-03-31 | 0.09 | 0.01 | +15.86% |
| Q4 2023 | 2023-12-31 | 0.09 | 0.02 | +27.27% |
| Q3 2023 | 2023-09-30 | 0.09 | 0.02 | +27.99% |
| Q2 2023 | 2023-06-30 | 0.08 | 0.01 | +23.26% |
| Q1 2023 | 2023-03-31 | 0.08 | 0.02 | +28.19% |
| Q4 2022 | 2022-12-31 | 0.07 | 0.02 | +29.35% |
| Q3 2022 | 2022-09-30 | 0.07 | −0.01 | −8.21% |
| Q2 2022 | 2022-06-30 | 0.06 | 0.00 | +7.25% |
| Q1 2022 | 2022-03-31 | 0.06 | 0.01 | +11.89% |
| Q4 2021 | 2021-12-31 | 0.05 | 0.00 | +3.20% |
| Q3 2021 | 2021-09-30 | 0.07 | 0.02 | +48.43% |
| Q2 2021 | 2021-06-30 | 0.06 | 0.01 | +27.67% |
| Q1 2021 | 2021-03-31 | 0.06 | −0.03 | −35.46% |
| Q4 2020 | 2020-12-31 | 0.05 | −0.09 | −62.52% |
| Q3 2020 | 2020-09-30 | 0.05 | −0.07 | −58.66% |
| Q2 2020 | 2020-06-30 | 0.05 | −0.06 | −58.09% |
| Q1 2020 | 2020-03-31 | 0.09 | −0.02 | −20.15% |
| Q4 2019 | 2019-12-31 | 0.14 | 0.05 | +49.27% |
| Q3 2019 | 2019-09-30 | 0.12 | 0.04 | +48.29% |
| Q2 2019 | 2019-06-30 | 0.11 | −0.01 | −8.24% |
| Q1 2019 | 2019-03-31 | 0.11 | — | — |
| Q4 2018 | 2018-12-31 | 0.09 | — | — |
| Q3 2018 | 2018-09-30 | 0.08 | — | — |
| Q2 2018 | 2018-06-30 | 0.12 | — | — |
Adaptimmune Therapeutics debt-to-assets ratio trends
Over the last five fiscal years, Adaptimmune Therapeutics's debt-to-assets ratio increased from 0.14 to 0.30, a change of 0.16. The latest reported quarter, Q2 2025, shows 0.37.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adaptimmune Therapeutics source filings ↗